|
1
|
Nielsen PE, Egholm M, Berg RH and Buchardt
O: Sequence-selective recognition of DNA by strand displacement
with a thymine-substituted polyamide. Science. 254:1497–1500. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nielsen PE: Targeting double stranded DNA
with peptide nucleic acid (PNA). Curr Med Chem. 8:545–550. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Borgatti M, Lampronti I, Romanelli A,
Pedone C, Saviano M, Bianchi N, Mischiati C and Gambari R:
Transcription factor decoy molecules based on a peptide nucleic
acid (PNA)-DNA chimera mimicking Sp1 binding sites. J Biol Chem.
278:7500–7509. 2003. View Article : Google Scholar
|
|
4
|
Gambari R: Peptide-nucleic acids (PNAs): A
tool for the development of gene expression modifiers. Curr Pharm
Des. 7:1839–1862. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gambari R: Biological activity and
delivery of peptide nucleic acids (PNA)-DNA chimeras for
transcription factor decoy (TFD) pharmacotherapy. Curr Med Chem.
11:1253–1263. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nielsen PE: Peptide nucleic acids (PNA) in
chemical biology and drug discovery. Chem Biodivers. 7:786–804.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hatamoto M, Ohashi A and Imachi H: Peptide
nucleic acids (PNAs) antisense effect to bacterial growth and their
application potentiality in biotechnology. Appl Microbiol
Biotechnol. 86:397–402. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gambari R, Borgatti M, Bezzerri V, Nicolis
E, Lampronti I, Dechecchi MC, Mancini I, Tamanini A and Cabrini G:
Decoy oligodeoxyribonucleotides and peptide nucleic acids-DNA
chimeras targeting nuclear factor kappa-B: Inhibition of IL-8 gene
expression in cystic fibrosis cells infected with Pseudomonas
aeruginosa. Biochem Pharmacol. 80:1887–1894. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pandey VN, Upadhyay A and Chaubey B:
Prospects for antisense peptide nucleic acid (PNA) therapies for
HIV. Expert Opin Biol Ther. 9:975–989. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nielsen PE: Gene targeting and expression
modulation by peptide nucleic acids (PNA). Curr Pharm Des.
16:3118–3123. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Manicardi A, Fabbri E, Tedeschi T, Sforza
S, Bianchi N, Brognara E, Gambari R, Marchelli R and Corradini R:
Cellular uptakes, biostabilities and anti-miR-210 activities of
chiral arginine-PNAs in leukaemic K562 cells. ChemBioChem.
13:1327–1337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fabbri E, Manicardi A, Tedeschi T, Sforza
S, Bianchi N, Brognara E, Finotti A, Breveglieri G, Borgatti M,
Corradini R, et al: Modulation of the biological activity of
microRNA-210 with peptide nucleic acids (PNAs). ChemMedChem.
6:2192–2202. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gambari R, Fabbri E, Borgatti M, Lampronti
I, Finotti A, Brognara E, Bianchi N, Manicardi A, Marchelli R and
Corradini R: Targeting microRNAs involved in human diseases: A
novel approach for modification of gene expression and drug
development. Biochem Pharmacol. 82:1416–1429. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fabani MM and Gait MJ: miR-122 targeting
with LNA/2′-O-methyl oligonucleotide mixmers, peptide nucleic acids
(PNA), and PNA-peptide conjugates. RNA. 14:336–346. 2008.
View Article : Google Scholar :
|
|
15
|
Fabani MM, Abreu-Goodger C, Williams D,
Lyons PA, Torres AG, Smith KG, Enright AJ, Gait MJ and Vigorito E:
Efficient inhibition of miR-155 function in vivo by peptide nucleic
acids. Nucleic Acids Res. 38:4466–4475. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brown PN and Yin H: PNA-based microRNA
inhibitors elicit anti-inflammatory effects in microglia cells.
Chem Commun (Camb). 49:4415–4417. 2013. View Article : Google Scholar
|
|
17
|
Brognara E, Fabbri E, Aimi F, Manicardi A,
Bianchi N, Finotti A, Breveglieri G, Borgatti M, Corradini R,
Marchelli R, et al: Peptide nucleic acids targeting miR-221
modulate p27Kip1 expression in breast cancer MDA-MB-231
cells. Int J Oncol. 41:2119–2127. 2012.PubMed/NCBI
|
|
18
|
Cheng CJ, Bahal R, Babar IA, Pincus Z,
Barrera F, Liu C, Svoronos A, Braddock DT, Glazer PM, Engelman DM,
et al: MicroRNA silencing for cancer therapy targeted to the tumour
microenvironment. Nature. 518:107–110. 2015. View Article : Google Scholar :
|
|
19
|
He L and Hannon GJ: MicroRNAs: Small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Piva R, Spandidos DA and Gambari R: From
microRNA functions to microRNA therapeutics: Novel targets and
novel drugs in breast cancer research and treatment (Review). Int J
Oncol. 43:985–994. 2013.PubMed/NCBI
|
|
21
|
Taylor MA and Schiemann WP: Therapeutic
opportunities for targeting microRNAs in cancer. Mol Cell Ther.
2:1–13. 2014. View Article : Google Scholar
|
|
22
|
Song MS and Rossi JJ: The anti-miR21
antagomir, a therapeutic tool for colorectal cancer, has a
potential synergistic effect by perturbing an
angiogenesis-associated miR30. Front Genet. 4:3012014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nana-Sinkam SP and Croce CM: Clinical
applications for microRNAs in cancer. Clin Pharmacol Ther.
93:98–104. 2013. View Article : Google Scholar
|
|
24
|
Hermansen SK and Kristensen BW: MicroRNA
biomarkers in glioblastoma. J Neurooncol. 114:13–23. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shu M, Zheng X, Wu S, Lu H, Leng T, Zhu W,
Zhou Y, Ou Y, Lin X, Lin Y, et al: Targeting oncogenic miR-335
inhibits growth and invasion of malignant astrocytoma cells. Mol
Cancer. 10:592011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chan XH, Nama S, Gopal F, Rizk P, Ramasamy
S, Sundaram G, Ow GS, Ivshina AV, Tanavde V, Haybaeck J, et al:
Targeting glioma stem cells by functional inhibition of a
prosurvival oncomiR-138 in malignant gliomas. Cell Reports.
2:591–602. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wagenaar TR, Zabludoff S, Ahn SM, Allerson
C, Arlt H, Baffa R, Cao H, Davis S, Garcia-Echeverria C, Gaur R, et
al: Anti-miR-21 suppresses hepatocellular carcinoma growth via
broad transcriptional network de-regulation. Mol Cancer Res.
13:1009–1021. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ma L, Reinhardt F, Pan E, Soutschek J,
Bhat B, Marcusson EG, Teruya-Feldstein J, Bell GW and Weinberg RA:
Therapeutic silencing of miR-10b inhibits metastasis in a mouse
mammary tumor model. Nat Biotechnol. 28:341–347. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shah MY and Calin GA: MicroRNAs miR-221
and miR-222: A new level of regulation in aggressive breast cancer.
Genome Med. 3:562011. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lambertini E, Lolli A, Vezzali F,
Penolazzi L, Gambari R and Piva R: Correlation between Slug
transcription factor and miR-221 in MDA-MB-231 breast cancer cells.
BMC Cancer. 12:4452012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Galardi S, Mercatelli N, Giorda E,
Massalini S, Frajese GV, Ciafrè SA and Farace MG: miR-221 and
miR-222 expression affects the proliferation potential of human
prostate carcinoma cell lines by targeting p27Kip1. J
Biol Chem. 282:23716–23724. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang J, Zhang JY, Chen J, Xu Y, Song NH
and Yin CJ: Prognostic role of microRNA-221 in various human
malignant neoplasms: A meta-analysis of 20 related studies. PLoS
One. 9:e876062014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li W, Guo F, Wang P, Hong S and Zhang C:
miR-221/222 confers radioresistance in glioblastoma cells through
activating Akt independent of PTEN status. Curr Mol Med.
14:185–195. 2014. View Article : Google Scholar
|
|
34
|
Chen L, Zhang J, Han L, Zhang A, Zhang C,
Zheng Y, Jiang T, Pu P, Jiang C and Kang C: Downregulation of
miR-221/222 sensitizes glioma cells to temozolomide by regulating
apoptosis independently of p53 status. Oncol Rep. 27:854–860.
2012.
|
|
35
|
Zhang CZ, Zhang JX, Zhang AL, Shi ZD, Han
L, Jia ZF, Yang WD, Wang GX, Jiang T, You YP, et al: MiR-221 and
miR-222 target PUMA to induce cell survival in glioblastoma. Mol
Cancer. 9:2292010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Brognara E, Fabbri E, Bazzoli E, Montagner
G, Ghimenton C, Eccher A, Cantù C, Manicardi A, Bianchi N, Finotti
A, et al: Uptake by human glioma cell lines and biological effects
of a peptide-nucleic acids targeting miR-221. J Neurooncol.
118:19–28. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jensen KK, Orum H, Nielsen PE and Nordén
B: Kinetics for hybridization of peptide nucleic acids (PNA) with
DNA and RNA studied with the BIAcore technique. Biochemistry.
36:5072–5077. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Corradini R, Feriotto G, Sforza S,
Marchelli R and Gambari R: Enhanced recognition of cystic fibrosis
W1282X DNA point mutation by chiral peptide nucleic acid probes by
a surface plasmon resonance biosensor. J Mol Recognit. 17:76–84.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cao X, Gu Y, Jiang L, Wang Y, Liu F, Xu Y,
Deng J, Nan Y, Zhang L, Ye J, et al: A new approach to screening
cancer stem cells from the U251 human glioma cell line based on
cell growth state. Oncol Rep. 29:1013–1018. 2013.
|
|
40
|
Abdullah Thani NA, Sallis B, Nuttall R,
Schubert FR, Ahsan M, Davies D, Purewal S, Cooper A and Rooprai HK:
Induction of apoptosis and reduction of MMP gene expression in the
U373 cell line by polyphenolics in Aronia melanocarpa and by
curcumin. Oncol Rep. 28:1435–1442. 2012.PubMed/NCBI
|
|
41
|
Pen A, Durocher Y, Slinn J, Rukhlova M,
Charlebois C, Stanimirovic DB and Moreno MJ: Insulin-like growth
factor binding protein 7 exhibits tumor suppressive and vessel
stabilization properties in U87MG and T98G glioblastoma cell lines.
Cancer Biol Ther. 12:634–646. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Rothbard JB, Kreider E, VanDeusen CL,
Wright L, Wylie BL and Wender PA: Arginine-rich molecular
transporters for drug delivery: Role of backbone spacing in
cellular uptake. J Med Chem. 45:3612–3618. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Abes R, Arzumanov A, Moulton H, Abes S,
Ivanova G, Gait MJ, Iversen P and Lebleu B: Arginine-rich cell
penetrating peptides: Design, structure-activity, and applications
to alter pre-mRNA splicing by steric-block oligonucleotides. J Pept
Sci. 14:455–460. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bhatia B: On the move: p27Kip1
drives cell motility in glioma cells. Cell Cycle. 9:1231–1240.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lu X, Zhao P, Zhang C, Fu Z, Chen Y, Lu A,
Liu N, You Y, Pu P and Kang C: Analysis of miR-221 and p27
expression in human gliomas. Mol Med Rep. 2:651–656.
2009.PubMed/NCBI
|
|
46
|
Gillies JK and Lorimer IA: Regulation of
p27Kip1 by miRNA 221/222 in glioblastoma. Cell Cycle.
6:2005–2009. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ueda R, Kohanbash G, Sasaki K, Fujita M,
Zhu X, Kastenhuber ER, McDonald HA, Potter DM, Hamilton RL, Lotze
MT, et al: Dicer-regulated microRNAs 222 and 339 promote resistance
of cancer cells to cytotoxic T-lymphocytes by down-regulation of
ICAM-1. Proc Natl Acad Sci USA. 106:10746–10751. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zerrouqi A, Pyrzynska B, Febbraio M, Brat
DJ and Van Meir EG: P14ARF inhibits human glioblastoma-induced
angiogenesis by upregulating the expression of TIMP3. J Clin
Invest. 122:1283–1295. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wang Y, Wang X, Zhang J, Sun G, Luo H,
Kang C, Pu P, Jiang T, Liu N and You Y: MicroRNAs involved in the
EGFR/PTEN/AKT pathway in gliomas. J Neurooncol. 106:217–224. 2012.
View Article : Google Scholar
|
|
50
|
Bertucci A, Lülf H, Septiadi D, Manicardi
A, Corradini R and De Cola L: Intracellular delivery of peptide
nucleic acid and organic molecules using zeolite-L nanocrystals.
Adv Healthcare Mater. 3:1812–1817. 2014. View Article : Google Scholar
|
